Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Apollomics Inc. - Warrant
(NQ:
APLMW
)
0.0129
-0.0001 (-0.77%)
Streaming Delayed Price
Updated: 12:28 PM EST, Jan 7, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Apollomics Inc. - Warrant
< Previous
1
2
3
Next >
Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results
March 28, 2024
From
Apollomics Inc.
Via
GlobeNewswire
Apollomics to Announce Full Year 2023 Financial Results and Host Conference Call on March 28, 2024
March 26, 2024
From
Apollomics Inc.
Via
GlobeNewswire
Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer
March 04, 2024
From
Apollomics Inc.
Via
GlobeNewswire
Apollomics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 07, 2024
From
Apollomics Inc.
Via
GlobeNewswire
Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
January 19, 2024
Apollomics has an initial 180-day period through July 15, 2024 to regain compliance with Minimum Bid Price Requirement
From
Apollomics Inc.
Via
GlobeNewswire
Apollomics to Participate in a Fireside Chat at the B. Riley Securities’ 2024 Virtual Oncology Conference
January 17, 2024
From
Apollomics Inc.
Via
GlobeNewswire
Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia
January 03, 2024
From
Apollomics Inc.
Via
GlobeNewswire
Apollomics to Present at the 2024 Biotech Showcase
January 02, 2024
From
Apollomics Inc.
Via
GlobeNewswire
Apollomics Presents Interim Data from Two Ongoing Phase 2 Clinical Trials with Vebreltinib in NSCLC Patients with MetExon14 Skipping Mutation
December 04, 2023
From
Apollomics Inc.
Via
GlobeNewswire
Apollomics to Participate in a Fireside Chat at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference
November 29, 2023
From
Apollomics Inc.
Via
GlobeNewswire
Apollomics Announces Presentation of Vebreltinib Data at the 2023 IASLC North America Conference on Lung Cancer (NACLC)
November 28, 2023
From
Apollomics Inc.
Via
GlobeNewswire
Apollomics Announces the First Approval of Vebreltinib for MET Exon 14 Skip Non-Small Cell Lung Cancer
November 16, 2023
From
Apollomics Inc.
Via
GlobeNewswire
Apollomics Announces Two New Cohorts in Global Phase 2 SPARTA Study of Vebreltinib in Non-Small Cell Lung Cancer and Other Solid Tumors with MET Dysregulation
October 31, 2023
From
Apollomics Inc.
Via
GlobeNewswire
Apollomics Announces Report of Activity of Vebreltinib in Glioblastoma Multiforme (GBM) with PTPRZ-MET Fusion
October 26, 2023
From
Apollomics Inc.
Via
GlobeNewswire
Apollomics Announces Efficacy of Vebreltinib in NSCLC Patients with MetEx14 Skipping Mutation Achieving an Overall Response Rate (ORR) of 75%
October 23, 2023
From
Apollomics Inc.
Via
GlobeNewswire
Apollomics Announces Presentations of Vebreltinib Data at ESMO 2023
October 16, 2023
From
Apollomics Inc.
Via
GlobeNewswire
Apollomics Reports First Half 2023 Financial Results and Provides Corporate Update
September 28, 2023
From
Apollomics Inc.
Via
GlobeNewswire
Apollomics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 06, 2023
From
Apollomics Inc.
Via
GlobeNewswire
Apollomics Co-Founder and President, Sanjeev Redkar, Ph.D., to Speak at 23rd Annual R. Bryan Miller Symposium
April 11, 2023
Dr. Redkar to discuss importance of HGF/cMET pathway, which can play critical role in origin of several cancers
From
Apollomics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
